DEXTENZA Drug Patent Profile

Which patents cover Dextenza, and when can generic versions of Dextenza launch?

Dextenza is a drug marketed by Ocular Therapeutix and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-four patent family members in six countries.

The generic ingredient in DEXTENZA is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dextenza

A generic version of DEXTENZA was approved as dexamethasone by PANGEA on April 28^th, 1983.

Summary for DEXTENZA

International Patents:	24
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	46
Drug Prices:	Drug price information for DEXTENZA
What excipients (inactive ingredients) are in DEXTENZA?	DEXTENZA excipients list
DailyMed Link:	DEXTENZA at DailyMed

See drug prices for DEXTENZA

Recent Clinical Trials for DEXTENZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Maanasa Indaram, MD	PHASE1
Wyse Eyecare	Phase 4
Duke University	Early Phase 1

See all DEXTENZA clinical trials

Pharmacology for DEXTENZA

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for DEXTENZA

DEXTENZA is protected by seven US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	8,563,027
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	8,409,606		Y
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	12,144,889
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	12,150,896
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	11,458,041

Expired US Patents for DEXTENZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018	9,254,267

EU/EMA Drug Approvals for DEXTENZA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

International Patents for DEXTENZA

See the table below for patents covering DEXTENZA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017062770
Canada	3177005	PROCEDES DE TRAITEMENT DE LA CONJONCTIVITE ALLERGIQUE (METHODS OF TREATING ALLERGIC CONJUNCTIVITIS)
China	115768385	治疗过敏性结膜炎的方法 (Methods of treating allergic conjunctivitis)
European Patent Office	4142664	PROCÉDÉS DE TRAITEMENT DE LA CONJONCTIVITE ALLERGIQUE (METHODS OF TREATING ALLERGIC CONJUNCTIVITIS)
World Intellectual Property Organization (WIPO)	2021222117
World Intellectual Property Organization (WIPO)	2017062770

Supplementary Protection Certificates for DEXTENZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193	SPC/GB12/047	United Kingdom		PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727

Last updated: July 20, 2026

XTENZA (dexamethasone ophthalmic insert): market dynamics and financial trajectory

DEXTENZA has niche positioning in ophthalmology for steroid-responsive inflammation of the eye following ocular surgery, with revenue largely driven by surgery volumes, formulary adoption, and replacement of older steroid drops. Financial trajectory is constrained by (1) limited label breadth versus broader-use corticosteroid regimens, (2) payer and channel preference for generics or lower-cost drop alternatives, and (3) competition from other ophthalmic steroid products and less expensive delivery formats.

What is DEXTENZA and what market does it address (US ophthalmology)?

Fast answer: DEXTENZA is a dexamethasone ophthalmic insert indicated for steroid-responsive inflammation associated with ocular surgery. Commercial demand correlates with cataract and other post-surgical prescribing patterns, plus perioperative treatment protocols that favor sustained drug delivery.

What are the core commercial use drivers?

• Ocular surgery volume: Cataract surgery remains the dominant driver of postoperative inflammation treatment demand in the US market.
• Staging and adherence: The insert is designed to provide local, sustained corticosteroid exposure, aiming to reduce dosing frequency versus drops.
• Prescriber protocol fit: Uptake depends on surgeon/clinic preference for postoperative anti-inflammatory regimens.
• Payer coverage and site-of-care economics: Reimbursement can determine whether clinics prefer branded inserts versus off-patent steroid drops or compounded alternatives.

What demand is typically “sensitive” to payer economics?

• Commercial vs Medicare mix: Clinics treating higher proportions of commercially insured patients often have greater flexibility to use branded postoperative regimens if formularies allow.
• Step edits: Formularies may prefer lower-cost steroid drops unless the insert is placed on preferred tiers with documented clinical value.

How has DEXTENZA performed financially and what does its revenue trajectory imply?

Fast answer: DEXTENZA’s financial path reflects a branded niche product with constrained addressable populations and moderate penetration rather than broad primary-care scale. Revenue trajectory depends on sustained uptake within postoperative protocols and any replacement of drop-based regimens.

Market-size logic behind a niche ophthalmic branded insert

• Smaller use population than chronic ophthalmic therapies: DEXTENZA is procedural, not chronic. That limits ceiling revenue compared with glaucoma or dry eye maintenance products.
• Channel consolidation: Large ophthalmology groups can exert strong formulary pressure, affecting brand adoption.
• Tendering and preference dynamics: Some systems standardize postoperative sets, reducing brand switching.

What financial milestones typically matter for this product category

Even without product-specific sales figures in this prompt context, investors and licensors generally track:

• New prescriber starts and refill/repeat adoption within surgery centers and large group practices.
• Inventory turns and distributor buy rates after launches and any label or competitiveness changes.
• Net-to-gross pressure from contracting and rebates when generics or lower-cost alternatives gain share.

What patent estate and exclusivity shape DEXTENZA pricing power?

Fast answer: Branded ophthalmic inserts typically have exclusivity anchored in formulation and delivery system patents plus composition and method patents for steroid use. Exclusivity strength drives the period during which DEXTENZA can sustain premium pricing against generics and substitution.

What patent types usually matter for insert products?

• Delivery system patents: Size, shape, material, drug release kinetics, and implantation method.
• Formulation patents: Dexamethasone concentration, particle/crystal form, excipients, and release profile.
• Use and method patents: Postoperative inflammation indications and dosing schedules.

When does exclusivity typically end for ophthalmic inserts?

Commercial risk escalates in the window where:

• composition of matter protection expires,
• formulation/delivery patents expire or become easier to design around, and
• FDA pathway entry becomes available for generic or 505(b)(2) products using modified delivery or release profiles.

Which competitors pressure DEXTENZA market share and pricing?

Fast answer: DEXTENZA competes against (1) other ophthalmic dexamethasone steroid products and (2) cheaper corticosteroid drop regimens used postoperatively.

Competitive pressure points by category

• Steroid drops (off-patent): Often lower cost with broad access; strong substitutes in payer formularies.
• Other delivery systems: Ophthalmic suspensions, newer branded steroid regimens, or alternative sustained-release formats can shift prescriber preference.
• Non-insert clinical workflow fit: Some clinics prioritize simplicity over sustained inserts if administrative burden or device handling is a concern.

How does competitive intensity translate into financial outcomes?

• Higher rebate pressure: Brands facing generic substitution often cut net prices via contracts.
• Share dilution: Even modest penetration by substitutes reduces revenue growth in niche products.
• Reduced conversion: New surgeon adopters may start with generics rather than branded inserts during periods of heightened cost scrutiny.

What is the Orange Book status of DEXTENZA and how does it affect generic entry risk?

Fast answer: DEXTENZA’s Orange Book listing(s) determine whether generic applicants can pursue ANDA or 505(b)(2) routes and what patents would be listed for Paragraph IV challenges.

How Orange Book listings map to entry risk

• If multiple formulation/delivery patents are listed: Generic entry is delayed or faces litigation risk.
• If only limited patents remain: Entry risk rises through easier design-around or faster resolution of patent challenges.
• If the listed patents are method-of-use dependent: Generic applicants may seek carve-outs or rely on alternative labeling approaches.

What litigation or Paragraph IV challenges affect DEXTENZA?

Fast answer: DEXTENZA’s generic entry timeline depends on whether any Paragraph IV certifications target its Orange Book-listed patents and whether those challenges trigger statutory stay periods.

What to monitor in DEXTENZA patent litigation (investor and licensing view)

• Filed Paragraph IV ANDAs or 505(b)(2) applications and the patents challenged.
• Court outcomes that determine whether challengers can launch on or before key expiration dates.
• Settlement agreements that establish “launch-at” dates and authorized generic arrangements.

What is the FDA regulatory pathway for DEXTENZA and how can it impact competition?

Fast answer: For a branded ophthalmic insert, FDA competition can come via ANDA (if eligible) or via 505(b)(2) pathway using literature or bridging studies, depending on listed patents and reference reliance.

Practical regulatory implications

• Bioequivalence feasibility: Ophthalmic local delivery can complicate straightforward equivalence, which often favors branded incumbents for a period.
• Bridging study burden: Competitors may need dose-release and clinical endpoint support, delaying launch and increasing cost.

What formulations and delivery-system details matter for IP and design-around?

Fast answer: Sustained-release delivery-system parameters create the main design-around surface for ophthalmic inserts, which can delay “true substitutability” even when dexamethasone itself is off-patent.

What design-around strategies are typical in this space

• Altered release kinetics: Changing insertion size/material structure to change drug diffusion profile.
• Different excipient or particle characteristics: Adjusting formulation to avoid specific composition claims.
• Different dosing schedule: Reconfiguring exposure duration to fall outside method-of-use claims.

How does DEXTENZA compare with alternative postoperative steroid regimens?

Fast answer: The competitive question is not just efficacy, but workflow fit and total cost of treatment. Inserts can reduce dosing frequency but may face higher sticker price and payer constraints.

Comparison dimensions used in US adoption decisions

• Clinical endpoint alignment: Reduced inflammation control and sustained effect relative to drops.
• Dosing burden: Surgeon and clinic preference for device insertion versus bottle dispensing.
• Payer reimbursement: Copays and reimbursement policies for branded inserts.
• Patient handling: Device acceptability and technique requirements.

Where is revenue exposure highest for DEXTENZA (brand concentration risks)?

Fast answer: Revenue concentration risk typically sits with a limited number of prescribing ecosystems: cataract surgery centers, hospital outpatient surgery, and large ophthalmology groups that standardize postoperative sets.

Revenue sensitivity factors

• Surgery volumes and seasonality: Postoperative demand follows procedure patterns.
• Formulary churn: Contract renewals can quickly shift preferred agents.
• Substitution timing: When lower-cost alternatives gain formulary placement, branded insert demand softens.

What commercial strategy levers determine whether DEXTENZA grows or stalls?

Fast answer: Growth depends on converting postoperative protocols to sustained insert use, maintaining favorable formulary access, and defending net price against substitute generics or lower-cost branded alternatives.

Key strategy levers

• Account-based formulary management: Tiers, prior authorization criteria, and bundling into postoperative sets.
• Clinical evidence packaging: Translating clinical outcomes into payer-friendly value narratives (reduced dosing, adherence, sustained control).
• Channel alignment: Ensuring stable availability to prevent lost adoption due to supply or purchasing friction.

Key Takeaways

• DEXTENZA is a niche branded ophthalmic steroid insert with demand tied to ocular surgery workflows and postoperative inflammation protocols.
• Financial trajectory is limited by procedural use population, payer and channel preference dynamics, and substitution from lower-cost steroid drops.
• Patent and Orange Book status typically govern generic entry risk for ophthalmic inserts, with design-around complexity concentrated in delivery system and release profile IP.
• Competitive pressure and net price erosion are the main mechanisms that determine whether revenue can expand beyond initial penetration.

FAQs

1. Does DEXTENZA compete more with branded steroids or generic dexamethasone eye drops?
2. How do cataract surgery volumes translate into demand for postoperative ocular anti-inflammatory products like DEXTENZA?
3. What Orange Book patent categories most often delay generic competition for ophthalmic inserts?
4. What settlement dynamics are common when ANDA filers challenge Orange Book-listed patents for ophthalmic products?
5. How does payer formulary placement affect net revenue for branded ophthalmic drug-device combinations?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. Hatch-Waxman Act provisions (35 U.S.C. § 271(e)(2), 21 U.S.C. § 355(j)) and FDA Paragraph IV framework. U.S. Food and Drug Administration.